Phase I: First-in-Human Studies

Understand why Phase I trials are the critical first step in human testing, who participates, and how dose escalation protects the earliest volunteers.

What you will learn

By the end of this lesson, you will be able to:

1
Define the primary purpose of Phase I clinical trials and explain why safety is the paramount concern
2
Identify who typically participates in Phase I studies and explain the rationale for participant selection
3
Describe common Phase I study designs, including Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) approaches
4
Explain dose escalation methods such as the 3+3 design and Bayesian adaptive approaches
5
Define Maximum Tolerated Dose (MTD) and explain how it guides dose selection for later trials
6
Identify the key pharmacokinetic and pharmacodynamic parameters measured in Phase I studies
7
Recognize the specialized environments and intensive monitoring requirements of first-in-human studies

Timed blood samples are collected throughout Phase I trials to map the drug's absorption and elimination (pharmacokinetics).

You're already ahead of most

This lesson is part of a complete GCP certification track — 2 courses, quizzes, a final exam, and a certificate recognized by 18+ trial sponsors. It's entirely free.

Good Clinical Practice (GCP)1 of 2

Free Lesson Preview

Module 1: Lesson 1

Phase I: First-in-Human Studies

Understand why Phase I trials are the critical first step in human testing, who participates, and how dose escalation protects the earliest volunteers.

What you will learn

By the end of this lesson, you will be able to:

1
Define the primary purpose of Phase I clinical trials and explain why safety is the paramount concern
2
Identify who typically participates in Phase I studies and explain the rationale for participant selection
3
Describe common Phase I study designs, including Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) approaches
4
Explain dose escalation methods such as the 3+3 design and Bayesian adaptive approaches
5
Define Maximum Tolerated Dose (MTD) and explain how it guides dose selection for later trials
6
Identify the key pharmacokinetic and pharmacodynamic parameters measured in Phase I studies
7
Recognize the specialized environments and intensive monitoring requirements of first-in-human studies

You're already ahead of most

This lesson is part of a complete GCP certification track — 2 courses, quizzes, a final exam, and a certificate recognized by 18+ trial sponsors. It's entirely free.